EAI001

• CAT Number: I026661
• CAS Number: 892772-75-7
• Molecular Formula: C19H15N3O2S
• Molecular Weight: 349.41
• Purity: 98%
• Synonyms: EAI001; EAI-001; EAI 001
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
• IUPAC Name: 2-(1-oxoisoindolin-2-yl)-2-phenyl-N-(thiazol-2-yl)acetamide
• InChI: InChI=1S/C19H15N3O2S/c23-17(21-19-20-10-11-25-19)16(13-6-2-1-3-7-13)22-12-14-8-4-5-9-15(14)18(22)24/h1-11,16H,12H2,(H,20,21,23)
• InChIKey: PWRVRDCBFYLYFU-UHFFFAOYSA-N
• SMILES: O=C(NC1=NC=CS1)C(N(CC2=C3C=CC=C2)C3=O)C4=CC=CC=C4

EAI001 (CAT: I026661) is a notable compound as it was the first non-ATP competitive inhibitor developed specifically to target the epidermal growth factor receptor (EGFR) mutations L858R, T790M, and C797S. These mutations are commonly found in EGFR-mutant non-small cell lung cancer (NSCLC) and are associated with resistance to traditional EGFR inhibitors. EAI001 was designed to bind to EGFR in a manner that is distinct from ATP binding, allowing it to overcome the resistance caused by these specific mutations. By selectively targeting these mutations, EAI001 demonstrated promising preclinical activity and provided a basis for the development of subsequent generations of non-ATP competitive EGFR inhibitors for the treatment of EGFR-mutant NSCLC.